Amir Baghbanzadeh
Overview
Explore the profile of Amir Baghbanzadeh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1128
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bakhshivand M, Masoumi J, Ghorbaninezhad F, Aghebati-Maleki L, Shanebandi D, Sandoghchian Shotorbani S, et al.
Heliyon
. 2024 Sep;
10(18):e37699.
PMID: 39309891
Anticancer immunotherapies with a dendritic Cell (DC) basis are becoming more popular. However, it has been suggested that the tumor's immunosuppressive mechanisms, such as inhibitory immunological checkpoint molecules, reduce the...
2.
Mardi A, Alizadeh M, Abdolalizadeh A, Baghbanzadeh A, Baradaran B, Aghebaqti-Maleki A, et al.
Med Oncol
. 2024 Jul;
41(8):193.
PMID: 38955918
Preclinical and clinical research showed that immune checkpoint blockade provides beneficial effects for many patients with liver cancer. This study aimed to assess the effect of CTLA-4-specific siRNA on the...
3.
Jalilzadeh N, Barzgar Barough N, Karami M, Baghbanzadeh A, Velaei K
Bioimpacts
. 2024 Jun;
14(3):27591.
PMID: 38938757
Introduction: Understanding the key role of the tumor microenvironment in specifying molecular markers of breast cancer subtypes is of a high importance in diagnosis and treatment. Therefore, the possibility of...
4.
Shadbad M, Baghbanzadeh A, Baradaran B
EXCLI J
. 2024 Apr;
23:384-400.
PMID: 38655096
Glioblastoma multiform (GBM) is a commonly diagnosed brain neoplasm with a poor prognosis. Accumulating evidence has highlighted the significance of microRNA (miR) dysregulation in tumor development and progression. This study...
5.
Bilan F, Amini M, Doustvandi M, Tohidast M, Baghbanzadeh A, Hosseini S, et al.
Bioimpacts
. 2024 Mar;
14(2):27764.
PMID: 38505672
Introduction: Gastric cancer (GC) is the third leading cause of cancer-related death worldwide. microRNAs are a group of regulatory non-coding RNAs that are involved in GC progression. miR-145 as a...
6.
Jafari H, Mahami-Oskouei M, Spotin A, Baradaran B, Shanehbandi D, Baghbanzadeh A, et al.
J Trop Med
. 2024 Mar;
2024:7474039.
PMID: 38504949
Antigens in hydatid cyst fluid (HCF) have been discovered to bear a significant resemblance to antigens present in cancer cells. MicroRNA-1 (miR-1) is a well-known member of the tumor inhibitor...
7.
Dendritic cell vaccination strategy for the treatment of acute myeloid leukemia: a systematic review
Motallebzadeh Khanmiri J, Alizadeh M, Esmaeili S, Gholami Z, Safarzadeh A, Khani-Eshratabadi M, et al.
Cytotherapy
. 2024 Mar;
26(5):427-435.
PMID: 38483358
Background Aims: Acute myeloid leukemia (AML) is classified as a hematologic malignancy characterized by the proliferation of immature blood cells within the bone marrow (BM), resulting in an aberrant and...
8.
Dabbaghipour R, Ahmadi E, Entezam M, Farzam O, Baghbanzadeh A, Sichani A, et al.
Iran J Allergy Asthma Immunol
. 2024 Mar;
22(6):512-526.
PMID: 38477949
Scientific research over the past decades has proven the pivotal role of long non-coding RNAs (LncRNAs) in regulating gene expression. The immune responses are controlled through the interaction of pro-inflammatory...
9.
Masoumi J, Ghorbaninezhad F, Saeedi H, Safaei S, Shahgoli V, Ghaffari Jolfayi A, et al.
Biomedicines
. 2023 Dec;
11(12).
PMID: 38137433
Background: Gastric cancer, ranked as the fifth most common cancer worldwide, presents multiple treatment challenges. These obstacles often arise due to cancer stem cells, which are associated with recurrence, metastasis,...
10.
Hosseinkhani N, Hemmat N, Baghbani E, Baghbanzadeh A, Kazemi T, Mokhtarzadeh A, et al.
Gene
. 2023 Dec;
896:148043.
PMID: 38042220
Background: As inhibitory immune checkpoint molecules, cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and V-domain Ig suppressor of T-cell activation (VISTA) can be expressed in tumoral cells and facilitate immune evasion of tumoral...